Logo Image
Opinion|Videos|October 28, 2024

Incorporating Real-World Evidence for HER2+ NSCLC

Key Takeaways

  • Real-world evidence enhances understanding of HER2-directed therapies' effectiveness and safety in diverse populations, complementing clinical trial data.
  • Collaboration among payers, providers, and manufacturers is vital for equitable access to HER2-directed therapies and cost management.
SHOW MORE

Panelists discuss how real-world evidence plays a crucial role in shaping both clinical decision-making and coverage policies for HER2-directed therapies in NSCLC, while exploring collaborative strategies between payers, providers, and manufacturers to balance equitable access with cost management.

Episodes in this series

Video content above is prompted by the following:

  • What role do you see for real-world evidence in informing both clinical decision-making and coverage policies for HER2-directed therapies?
  • (Heymach) How can collaboration between payers, providers, and manufacturers be leveraged to ensure equitable access to HER2-directed therapies while managing costs?

Related Content